SYN - Synthetic Biologics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.5821
-0.0099 (-1.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.5920
Open0.5800
Bid0.0000 x 1400
Ask0.0000 x 800
Day's Range0.5640 - 0.5942
52 Week Range0.5100 - 11.2000
Volume224,705
Avg. Volume333,054
Market Cap9.012M
Beta (3Y Monthly)2.40
PE Ratio (TTM)N/A
EPS (TTM)-4.0580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.63
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT

    Q4 2018 Synthetic Biologics Inc Earnings Call

  • Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results
    PR Newswire2 months ago

    Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results

    -- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 -- -- Conference Call Wednesday, February ...

  • GlobeNewswire2 months ago

    Sýn hf. : Q4 Investors presentation

    See attached:  Investors presentation Q4 This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants that they are solely responsible ...

  • GlobeNewswire2 months ago

    Sýn hf. : Changes in management of Sýn hf.

    Stefán Sigurðsson, the CEO of Sýn hf., has in accordance with an agreement with the Board of Directors, requested to resign from his post, effective as of June 1st 2019. The Board of Directors has requested the Chairman of the Board to take on an active role as regards the organizational structure of the Company as well as ensuring that the operation of the Company will be in good order until a new CEO has been recruited. This announcement is distributed by West Corporation on behalf of West Corporation clients.

  • GlobeNewswire2 months ago

    Sýn hf. : Merged company completes its first full year under challenging market conditions

    Sýn`s 2018 annual financial statement was approved by Sýn`s CEO and board of directors at a board meeting 27th of February 2019. In December 2017 the company purchased certain assets and operations of 365 Miðlar hf., and this influences the comparison between periods. Sýn and the Faroese company Tjaldur have agreed on heads of terms in the merger of P/F Hey a subsidiary of Sýn and the Faroese IT company Nema a subsidiary of Tjaldur.

  • GlobeNewswire2 months ago

    Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F

    Reference is made to Stock Exchange announcement from November 1st 2018, according to which Sýn and the Faroese company Tjaldur had agreed heads of terms in relation to a merger of Hey, a subsidiary of Sýn, and the Faroese IT company Nema, a subsidiary of Tjaldur. This announcement is distributed by West Corporation on behalf of West Corporation clients.

  • Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019
    PR Newswire2 months ago

    Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019

    -- Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST -- ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored
    PR Newswire4 months ago

    Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored

    ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010's Phase 2b investigator-sponsored clinical study. SYN-010 is a proprietary, modified-release reformulation of lovastatin lactone designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). Cedars-Sinai Medical Center (CSMC) and Synthetic Biologics are co-funding the study, which will further assess the efficacy and safety of SYN-010 in patients diagnosed with IBS-C.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q3 2018 Synthetic Biologics Inc Earnings Call

  • GlobeNewswire5 months ago

    Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer

    Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.

  • GlobeNewswire5 months ago

    Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • New Trends in Healthcare Push Stocks Higher: 5 Picks
    Zacks5 months ago

    New Trends in Healthcare Push Stocks Higher: 5 Picks

    New healthcare trends backed by split party control of Congress are likely to boost industry stocks.

  • ACCESSWIRE5 months ago

    New Healthcare Trends Could Push Sector Stocks Higher

    CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.

  • Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
    PR Newswire5 months ago

    Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development

    ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated Clostridium difficile infection (CDI). Pursuant to the meeting, the FDA has proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval of ribaxamase on the basis of a single Phase 3 clinical trial.

  • Associated Press5 months ago

    Synthetic Biologics: 3Q Earnings Snapshot

    The Rockville, Maryland-based company said it had a loss of 93 cents per share. In the final minutes of trading on Thursday, the company's shares hit 88 cents. A year ago, they were trading at $24.30. ...

  • Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
    PR Newswire5 months ago

    Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

    -- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Strengthened Balance Sheet in Support of ...

  • Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
    PR Newswire6 months ago

    Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018

    -- Conference Call Scheduled for Thursday, November 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , Oct. 30, 2018 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...

  • Simply Wall St.6 months ago

    Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta?

    If you own shares in Synthetic Biologics Inc (NYSEMKT:SYN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Synthetic Biologics Announces Closing of $18,639,000 Public Offering
    PR Newswire6 months ago

    Synthetic Biologics Announces Closing of $18,639,000 Public Offering

    The securities offered by the Company consist of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at a combined price of $1.15 per Class A Unit, and (ii) Class B Units consisting of 15,723 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,672,173 shares of Common Stock, and Warrants to purchase 13,672,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five years from the date of issuance.

  • Synthetic Biologics Prices $18,000,000 Public Offering
    PR Newswire6 months ago

    Synthetic Biologics Prices $18,000,000 Public Offering

    The securities offered by the Company consist of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at a combined price of $1.15, and (ii) Class B Units consisting of 15,102 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,132,173 shares of Common Stock, and Warrants to purchase 13,132,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five years from the date of issuance.

  • Simply Wall St.7 months ago

    Who Are The Major Shareholders Of Synthetic Biologics Inc (NYSEMKT:SYN)?

    The big shareholder groups in Synthetic Biologics Inc (NYSEMKT:SYN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...

  • Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C
    PR Newswire7 months ago

    Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C

    ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has entered into an agreement with Cedars-Sinai Medical Center for an investigator-sponsored Phase 2 clinical study of SYN-010. The study will provide further evaluation of the efficacy and safety of SYN-010, the Company's modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by Cedars-Sinai Medical Center. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

  • Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswire8 months ago

    Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    ROCKVILLE, Md. , Aug. 30, 2018 /PRNewswire/ --  Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore ...

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT

    Q2 2018 Synthetic Biologics Inc Earnings Call